Litcius/Paper detail

Potential Inhibitors Against NDM-1 Type Metallo-β-Lactamases: An Overview

Smriti Sharma, Sumit Sharma, Parvinder Pal Singh, Inshad Ali Khan

2020Microbial Drug Resistance16 citationsDOI

Abstract

A new member of the class metallo-β-lactamase (MBL), New Delhi metallo-beta-lactamase 1 (NDM-1) has emerged recently as a leading threat to the treatment of infections that have spread in all major Gram-negative pathogens. The enzyme inactivates antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. This review provides information about NDM-1 spatial structure, potential features of the active site, and its mechanism of action. It also enlists the inhibitors/compounds/drugs against NDM-1 in various development phases. Understanding their mode of inhibition and the structure-activity relationship would be beneficial for development, synthesis, and even increasing biological efficacy of inhibitors, making them more promising drug candidates.

Topics & Concepts

AntibioticsMicrobiologyMode of actionBeta-Lactamase InhibitorsBiologyDrugCarbapenemPharmacologyBiochemistryAntibiotic Resistance in BacteriaTuberculosis Research and EpidemiologyPharmaceutical and Antibiotic Environmental Impacts
Potential Inhibitors Against NDM-1 Type Metallo-β-Lactamases: An Overview | Litcius